Program
Please use the download link at the right side of the webpage.
We are proud to announce the following list of invited speakers for the 5th Intl. Workshop on Clinical Pharmacology of Hepatitis Therapy:
Ribavirin - still needed, but how does it work
Jordan Feld, M.D., Toronto Western Hospital Liver Centre, Canada
Round Table Discussion: Regulatory requirements for early clinical testing of novel HCV antiviral drugs:
- The US (FDA) regulatory perspective
Jeffrey Murray, U.S. Food & Drug Administration
- The EU (EMEA) regulatory perspective
Jean-Michel Pawlotsky, M.D.,Ph.D., Université Paris XII, France
Novel Combination Therapies for Hepatitis treatment:
- Clinical pharmacology aspects
Patrick Smith, Ph.D., Roche, USA
- Virology aspects
Isabel Najera, Ph.D., Roche, USA
The role of PK enchancers/Boosting:
- Dale Kempf, Ph.D., Abbott, USA
- Anita Mathias, Ph.D., Gilead Science, USA
Confirmed Invited Speakers Joint Session (Morning 24 June):
The epidemic of HCV; globally and on genotype level. How does maturation of the HCV infected patient population (after 2015) impact drug development?
Gary Davis, M.D., Baylor University Medical Centre, USA
Dynamics of resistance and the implications for drug development.
Jean-Michel Pawlotsky, M.D., Ph.D., Hôpital Henri Mondor, Université Paris XII, France
New findings in HCV replication and how to apply to potential antiviral targets
Charles Rice, Ph.D., Rockefeller University, USA
Implications of genetic host polymorphism for HCV drug development and patient care
Mark Sulkowski, M.D., Ph.D., Johns Hopkins University, USA
